US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Xtrackers Nifty 500 India ETF

23.12

+0.12500.54%

Volume:2K

Turnover:56.47K

Market Cap:4.62M

PE:- -

High:23.28

Open:23.00

Low:23.00

Close:23.00

52wk High:27.40

52wk Low:20.52

Shares:200.00K

Float Shares:200.00K

Volume Ratio:16.14

T/O Rate:1.22%

Dividend:0.08

Dividend Rate:0.34%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Press Release: Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update

MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies

Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Splash Beverage Group Expands CannEpil® Platform into Veterinary Therapeutics, Establishing Second FDA-Regulated Pharmaceutical Development Program

Dyne Therapeutics receives FDA clearance to initiate DYNE-302 trial

Industrial Minerals pivots into gold with Laverton portfolio acquisition

Urban Company Sets Board Meeting and Earnings Call for Q1 FY2027 Results

Kelun Pharmaceutical's Subsidiary Kelun-Biotech Gets Approval for Clinical Trial of Novel Dual-Load ADC Drug SKB565

Press Release: NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to Its Board of Directors

Neumora Therapeutics Plans Q4 IND Filing for Obesity Drug After Repeat Toxicology Study

MT Newswires Live

Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting

RBI Intervention Boosts Rupee, Posting Biggest Single-Day Gain in Over a Month

Traders Reveal Central Bank Sold US Dollars in Foreign Exchange Markets to Support the Rupee

Oil Prices Decline, Indian Stock Market Rises for First Time in Six Days

Celltrion Submits Dual-Part EMA Application for Subcutaneous Rheumatoid Arthritis Drug

MT Newswires Live

Celltrion Submits South Korean IND for Subcutaneous Rheumatoid Arthritis Drug

MT Newswires Live

Indian Rupee Strengthens as Central Bank Intervenes in Onshore and Offshore Forex Markets

Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease

YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/IND/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IND","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","market":"US","secType":"STK","nameCN":"Xtrackers Nifty 500 India ETF","latestPrice":23.12,"timestamp":1787599057935,"preClose":22.995,"halted":0,"volume":2445,"delay":0,"changeRate":0.005435964340073929,"floatShares":200001,"shares":200001,"eps":0,"marketStatus":"Trading","change":0.125,"latestTime":"08-24 15:31:20 EDT","open":23,"high":23.28,"low":23,"amount":56474.49753,"amplitude":0.012177,"askPrice":23.13,"askSize":100,"bidPrice":23,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787601600000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":22.995,"sharesOutstanding":200001,"nav":23.031,"aum":4606217.85,"dividendRate":0.0034,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":23.1,"preClose":22.995,"latestTime":"09:29 EDT","volume":206,"amount":4758.869860000001,"timestamp":1787578199043,"change":0.105,"changeRate":0.004566,"amplitude":0.004784},"postHourTrading":{"tag":"盘后","latestPrice":22.885,"preClose":22.995,"latestTime":"16:10 EDT","volume":8,"amount":183.96,"timestamp":1787343004209,"change":-0.11,"changeRate":-0.004784,"amplitude":0},"volumeRatio":16.140399},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","floatShares":200001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":16.140399,"shares":200001,"dividePrice":0.0786,"high":23.28,"amplitude":0.012177,"preClose":22.995,"low":23,"week52Low":20.515,"pbRate":"--","week52High":27.4,"institutionHeld":0,"latestPrice":23.12,"eps":0,"divideRate":0.0034,"volume":2445,"delay":0,"ttmEps":0,"open":23,"prevYearClose":24.78,"prevWeekClose":22.995,"prevMonthClose":22.885,"prevQuarterClose":22.88,"fiveDayClose":23.005,"twentyDayClose":22.495,"sixtyDayClose":22.475},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IND\",params:#limit:5,,,undefined,":[{"date":"2026-06-18","symbol":"IND","amount":0.07775,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-18","defaultRemindTime":1781789400000,"name":"Xtrackers Nifty 500 India ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-18","currency":"USD","dateTimestamp":1781755200000,"payDate":"2026-06-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IND\",market:\"US\",,,undefined,":[{"executeDate":"2026-06-18","recordDate":"2026-06-18","paymentDate":"2026-06-26","value":0.07775,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IND\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IND\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2655872868","title":"Press Release: Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2655872868","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655872868?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:00","pubTimestamp":1785412800,"startTime":"0","endTime":"0","summary":"greatest potential for success. The strategy concentrates resources on. blarcamesine across three CNS indications: early Alzheimer's disease and. Rett syndrome, where the Company's clinical and regulatory foundation is. most advanced, and Fragile X, where FDA Orphan Drug Designation,supportive preclinical and biomarker data, and the absence of any. approved therapy may lead to a promising regulatory path with the FDA.Alzheimer's Disease Program-- At the end of March 2026, the Company opened an Investigational New Drug.  application for early Alzheimer's disease with the FDA. This is an. important milestone: the IND enables clinical studies to be conducted in. the U.S. and provides the basis for substantive discussions with the FDA. to align on the Company's future clinical development for early. -- Two foundational clinical pharmacology studies are proceeding","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","BK4081","BK4097","BK4585","BK4085","BK4022","R","BK4087","EMA","LU1878469433.USD","BK4110","DDI","BK4139","SOCL","ADME","BK4588","IND","CHMP","CNS","LABU","RPD","AAIC","AVXL","BK4232"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655687216","title":"MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2655687216","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655687216?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:00","pubTimestamp":1785412800,"startTime":"0","endTime":"0","summary":"Completion of 7-Day Toxicology and Pharmacokinetic Studies Advances Non-Opioid Pain Therapy and Obesity Candidate DevelopmentMIAMI, July  30, 2026  (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASD","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/30/3335999/0/en/MIRA-Pharmaceuticals-Progresses-MIRA-55-and-SKNY-1-Toward-IND-Enabling-Studies.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFXG1179.USD","LU1363072403.SGD","LU0149725797.USD","BK4007","LU0170899867.USD","IE00B1BXHZ80.USD","IND","LU0971096721.USD","BK4194","DEA","LU2237443622.USD","LU2237443978.SGD","LU0882574139.USD","CMC","LU2237443895.HKD","LU2746668461.USD","BK4223","LU2237443382.USD","MIRA","IE00BKVL7J92.USD","BK4006","IE00BZ1G4Q59.USD","LU2746668974.SGD","LU0267386448.USD","LU2237443549.SGD","IE00BHPRN162.USD","LU2237443465.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655872437","title":"Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2655872437","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655872437?lang=en_us&edition=fundamental","pubTime":"2026-07-30 19:35","pubTimestamp":1785411300,"startTime":"0","endTime":"0","summary":"Enrollment progressing in ASCEND Phase 1/2 global clinical trial evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients CR-00","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/30/3335951/0/en/Crescent-Biopharma-Reports-Second-Quarter-2026-Financial-Results-and-Recent-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4581","ORR","PFS","BK4195","IND","BK4585","BK4211","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655811687","title":"Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2655811687","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655811687?lang=en_us&edition=fundamental","pubTime":"2026-07-30 04:30","pubTimestamp":1785357000,"startTime":"0","endTime":"0","summary":"- Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 - - Completed enrollment o","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/29/3335623/0/en/Dyne-Therapeutics-Reports-Second-Quarter-2026-Financial-Results-and-Recent-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","GDOC","MEDX","BK4135","LABU","BK4585","DYN","BK4139","IDNA","HYLG","BK4588","REC","BK4505","CNS","NVIB","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655895044","title":"Splash Beverage Group Expands CannEpil® Platform into Veterinary Therapeutics, Establishing Second FDA-Regulated Pharmaceutical Development Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2655895044","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655895044?lang=en_us&edition=fundamental","pubTime":"2026-07-29 20:30","pubTimestamp":1785328200,"startTime":"0","endTime":"0","summary":"Expansion broadens CannEpil into veterinary therapeutics as Splash advances its cannabinoid pharmaceutical development platformFORT LAUDERDALE, Fla., July  29, 2026  (GLOBE NEWSWIRE) -- Splash Beverag","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/29/3335211/0/en/Splash-Beverage-Group-Expands-CannEpil-Platform-into-Veterinary-Therapeutics-Establishing-Second-FDA-Regulated-Pharmaceutical-Development-Program.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBD","LABU","BK4585","BK4539","THC","LU0648000940.SGD","BK4113","LU2324357040.USD","BK4007","LU1201861165.SGD","LENZ","BK4185","IEIH","LNGR","LU0963586101.USD","LU0130103400.USD","IND","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654009072","title":"Dyne Therapeutics receives FDA clearance to initiate DYNE-302 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2654009072","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654009072?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:40","pubTimestamp":1785238813,"startTime":"0","endTime":"0","summary":"Dyne Therapeutics (DYN) announced that it has received clearance from the FDA for its IND application to initiate a Phase 1 clinical trial for DYNE...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dyne-therapeutics-receives-fda-clearance-to-initiate-dyne-302-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dyne-therapeutics-receives-fda-clearance-to-initiate-dyne-302-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","DYNE","DYN","IDNA","BK4134","MEDX","BK4585","LABU","GDOC","BK4588","IND","HYLG","NVIB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654738930","title":"Industrial Minerals pivots into gold with Laverton portfolio acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2654738930","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654738930?lang=en_us&edition=fundamental","pubTime":"2026-07-28 12:57","pubTimestamp":1785214655,"startTime":"0","endTime":"0","summary":"Industrial Minerals Limited ( ($AU:IND) ) has provided an update. Industrial Minerals Ltd has agreed to acquire the Laverton Gold Portfolio in West...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/industrial-minerals-pivots-into-gold-with-laverton-portfolio-acquisition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/industrial-minerals-pivots-into-gold-with-laverton-portfolio-acquisition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDX","IAUM","XME","BEGS","RING","BAR","DULL","DUST","IAUI","UYM","GCmain","518880","SGCmain","IAU","IND","JDST","GDXD","PPI","GLTR","SGUmain","OUNZ","PHYS","1OZmain","DBC","GOAU","GDXJ","159934","BTGD","MGCmain","GLDM","AAAU","GDXU","JNUG","GLL","SHNY","UGL","USG","DGP","SGDM","GDXY","PICK","CEF","DZZ","MTX","FGDL","SGOL","NUGT","GBUG","GOLY","GLD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654047418","title":"Urban Company Sets Board Meeting and Earnings Call for Q1 FY2027 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2654047418","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654047418?lang=en_us&edition=fundamental","pubTime":"2026-07-28 03:14","pubTimestamp":1785179656,"startTime":"0","endTime":"0","summary":"An update from Urban Company Limited ( ($IN:URBANCO) ) is now available. Urban Company Limited, a listed Indian marketplace for home and personal s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/urban-company-sets-board-meeting-and-earnings-call-for-q1-fy2027-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/urban-company-sets-board-meeting-and-earnings-call-for-q1-fy2027-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SCIN","IND","EPI","BK4588","FLIN","PIN","INDY","BK4585","SMIN","NFTY","BK4523","INDL","INDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142348091","title":"Kelun Pharmaceutical's Subsidiary Kelun-Biotech Gets Approval for Clinical Trial of Novel Dual-Load ADC Drug SKB565","url":"https://stock-news.laohu8.com/highlight/detail?id=1142348091","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142348091?lang=en_us&edition=fundamental","pubTime":"2026-07-27 22:20","pubTimestamp":1785162017,"startTime":"0","endTime":"0","summary":"Sichuan Kelun Pharmaceutical Co.,Ltd. (SZ: 002422) has announced that its controlling subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., received a clinical trial approval notice from the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","PSYK","ADC","LU2148510915.USD","BK0239","MDTX","BK4231","IBBQ","BMED","LU1064130708.USD","BK0060","002422","LU1979443071.USD","IND","LU1064131003.USD","NETL","LU1934453819.USD","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654048668","title":"Press Release: NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2654048668","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654048668?lang=en_us&edition=fundamental","pubTime":"2026-07-27 21:00","pubTimestamp":1785157200,"startTime":"0","endTime":"0","summary":"CALABASAS, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (\"NeOnc\" or the \"Company\"), a multi-Phase 2 clinical-stage biopharmaceutical company developing no","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007","BK4232","IND","03160","BK4135","BK4604","CNS","BK4099","BK4585","R","TM","BK4588","BK4022","BK4555"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654010397","title":"Neumora Therapeutics Plans Q4 IND Filing for Obesity Drug After Repeat Toxicology Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2654010397","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654010397?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:21","pubTimestamp":1785154877,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics  said Monday a repeat safety study of its experimental oral obesity drug, NMRA-215, found no unexpected in-life adverse findings, supporting plans to file an investigational new drug application in the fourth quarter of 2026.The company said it repeated the 13-week rat study after an earlier study reported unexpected findings in five of 142 animals.Neumora said an audit found discrepancies that resulted in critical audit observations in how the earlier study was conducted, and the new results, along with previous studies in rats and dogs, suggest the earlier findings were not caused by NMRA-215.Neumora said its preclinical studies showed NMRA-215 produced weight loss as a monotherapy, increased weight loss when used with semaglutide, and improved markers linked to heart and metabolic health.It added that it expects to begin a Phase 1 clinical trial by the end of 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NMRA","BK4007","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654504582","title":"Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting","url":"https://stock-news.laohu8.com/highlight/detail?id=2654504582","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654504582?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:00","pubTimestamp":1785153600,"startTime":"0","endTime":"0","summary":"– Phase 2a study of CTEV in coronary artery bypass grafting (CABG) is expected to start this quarter – – Progression of CTEV into human study supported by positive preclinical results presented at mul","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/27/3333474/0/en/Humacyte-Announces-FDA-Acceptance-of-IND-for-First-In-Human-Clinical-Study-of-CTEV-for-Coronary-Artery-Bypass-Grafting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","LABU","CTEV","BK4588","BK4585","AV","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177586613","title":"RBI Intervention Boosts Rupee, Posting Biggest Single-Day Gain in Over a Month","url":"https://stock-news.laohu8.com/highlight/detail?id=1177586613","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177586613?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:48","pubTimestamp":1785152925,"startTime":"0","endTime":"0","summary":"India's central bank intervened heavily in the foreign exchange market on Monday, pushing the rupee to its largest single-day gain in over a month. This move was supported by falling international...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOPP","NFTY","IND","PIN","FLIN","INDE","BK4588","INDY","TAJX","SMIN","FLIBF","SCIN","INDA","GIND","INCO","IMVP","BK4523","INDL","INQQ","BK4585","EPI","NDIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199292205","title":"Traders Reveal Central Bank Sold US Dollars in Foreign Exchange Markets to Support the Rupee","url":"https://stock-news.laohu8.com/highlight/detail?id=1199292205","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199292205?lang=en_us&edition=fundamental","pubTime":"2026-07-27 17:00","pubTimestamp":1785142830,"startTime":"0","endTime":"0","summary":"Several traders, who requested anonymity, have disclosed that the Indian central bank sold US dollars in both onshore and offshore foreign exchange markets to stabilize the rupee's exchange rate. The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4523","INCO","SMIN","PIN","SCIN","EPI","TAJX","FLIBF","UUP","INDA","ASGM","INDL","IND","NDIA","INQQ","NFTY","INDE","INDY","IOPP","UDN","GIND","IMVP","BK4585","BK4588","FLIN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198175648","title":"Oil Prices Decline, Indian Stock Market Rises for First Time in Six Days","url":"https://stock-news.laohu8.com/highlight/detail?id=1198175648","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198175648?lang=en_us&edition=fundamental","pubTime":"2026-07-27 13:01","pubTimestamp":1785128483,"startTime":"0","endTime":"0","summary":"Indian stock markets advanced in early trading, snapping a five-day losing streak, as falling oil prices boosted investor sentiment across Asian markets. The Nifty50 index on the National Stock...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USL","WEEI","DRIP","XES","BCHI","QLVE","EEMA","BNO","STXE","DUG","TEMX","PIN","MEMX","DEXC","UGA","RAYE","XLEX","PEMX","DFAE","IMVP","DBE","EMXC","IOPP","SDOG","BKEM","INDE","VDE","KEMX","TEMR","HEEM","DIG","MFEM","BK4523","XSOE","INCO","PEJ","BK4585","XCEM","OILU","VOOV","OILK","GLIN","BK4550","DBO","FLIBF","BWET","NFTY","PXE","WTIU","INDH","XCNY","INQQ","EET","INDY","TAJX","VEU","SCIN","XC","IXC","EQLT","INDA","TPOR","SCHE","EMES","SPEM","INDL","MEM","BK4570","ASIA","PXJ","XXCH","SMIN","BK4588","USE","BKF","AEF","GIND","IEO","INDQ","SEEM","SPXT","FLIN","INDZ","FEMR","QEMM","FTXN","RWEM","EEMV","VEXC","BBEM","ERX","DBC","IND","NDIA","USOI","DRLL","UAE","GUSH","OILT","EPI","AVEM","OIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653088115","title":"Celltrion Submits Dual-Part EMA Application for Subcutaneous Rheumatoid Arthritis Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2653088115","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653088115?lang=en_us&edition=fundamental","pubTime":"2026-07-24 17:23","pubTimestamp":1784885030,"startTime":"0","endTime":"0","summary":"Celltrion  has submitted applications for its subcutaneous rheumatoid arthritis drug CT-P13 SC  to both the U.S. FDA  and the European Medicines Agency .The company seeks to demonstrate superiority over placebo at 12 weeks in a 296-patient, 52-week global Phase 3 trial, according to a bourse filing on Friday.The subcutaneous formulation, already approved for ulcerative colitis and Crohn's disease in multiple regions, aims to expand its indications and improve patient convenience through a broader treatment population.The company cautions that historically only about 10% of clinical trial drugs ultimately receive marketing approval, and results may fall short of expectations.While both filings share the same clinical design and commercial rationale, the EMA submission explicitly addresses the EU's revised Clinical Trials Regulation requiring separate Part 1  and Part 2  approvals.Both submissions support commercial differentiation through patient diversity, though investors are urged to","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7095","BK4081","IND","EMA","IND.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653700516","title":"Celltrion Submits South Korean IND for Subcutaneous Rheumatoid Arthritis Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2653700516","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653700516?lang=en_us&edition=fundamental","pubTime":"2026-07-24 16:49","pubTimestamp":1784882944,"startTime":"0","endTime":"0","summary":"Celltrion  has filed a Phase 3 IND application with the MFDS for CT-P13 SC  in rheumatoid arthritis, aiming to demonstrate superiority over placebo at 12 weeks.The 296-patient, 52-week trial seeks to expand the drug's approved uses beyond ulcerative colitis and Crohn's disease, leveraging its subcutaneous formulation for patient convenience, according to a bourse filing on Friday.The company cautions that only about 10% of trial drugs ultimately gain marketing approval, and outcomes may not meet expectations.This filing, confirmed on Friday, also supports commercial differentiation and regulatory trends favoring patient diversity, though investors should review all risk disclosures.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182433727","title":"Indian Rupee Strengthens as Central Bank Intervenes in Onshore and Offshore Forex Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=1182433727","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182433727?lang=en_us&edition=fundamental","pubTime":"2026-07-24 12:20","pubTimestamp":1784866849,"startTime":"0","endTime":"0","summary":"Traders, who requested anonymity as they were not authorized to speak publicly, reported that the Reserve Bank of India (RBI) sold US dollars in both the offshore and onshore foreign exchange markets...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PIN","BK4523","INDA","NFTY","INQQ","NDIA","EPI","BK4585","IOPP","INDE","GLIN","IMVP","IND","BK4588","SMIN","ASGM","INDY","FLIBF","TAJX","INDL","SCIN","FLIN","XCEM","INCO","IUmain","GIND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653773779","title":"Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2653773779","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653773779?lang=en_us&edition=fundamental","pubTime":"2026-07-24 04:05","pubTimestamp":1784837100,"startTime":"0","endTime":"0","summary":"-- FDA clearance of the IND, together with the previously cleared CTA, establishes a global Phase 1/2 clinical program for PM577a -- -- PM577a targets the H1069Q mutation in the ATP7B gene, the most p","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/23/3332566/0/en/Prime-Medicine-Announces-U-S-FDA-Clearance-of-Investigational-New-Drug-Application-for-PM577a-in-H1069Q-mutated-Wilson-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","COPJ","BK4535","CPXR","BK4585","COPP","CPER","ICOP","BK4588","BK4229","CTA","XME","IND","LABU","WD","UYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653747032","title":"YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services","url":"https://stock-news.laohu8.com/highlight/detail?id=2653747032","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653747032?lang=en_us&edition=fundamental","pubTime":"2026-07-23 20:00","pubTimestamp":1784808000,"startTime":"0","endTime":"0","summary":"Taipei, Taiwan, July  23, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and op","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/23/3332099/0/en/YD-Bio-and-EG-BioMed-Conclude-Successful-Exhibition-at-BIO-Asia-Taiwan-2026-Highlighting-Innovations-in-Ophthalmology-Oncology-Diagnostics-and-Clinical-Services.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4019","BK4588","IE00B19Z3581.USD","IND","BK4121","BIO","IE00B19Z3B42.SGD","LNGR","LU0077335932.USD","LU1169590202.USD","LU0211331839.USD","EG","IE0002270589.USD","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}